Biotech Values

[bellweather1]

Ponatinib/other TKIs-

DD,Thanks for that Gleveec/Tasigna stickiness chart.

Peter,

I guess the issue will be determined by how strong the long-term efficacy superiority of Pona is(and in which cohorts) when initiated 1st before other TKIs, and how statistically significant the effect is.

Thanks for the Gleevec color.

Any indications that other TKIs show similar advantages when started before Gleevec?; statistical significance?

Anyone aware of indications that Pona superior efficacy when employed earlier(before other TKIs) is likely to show statistically significant long-term efficacy(haven't attempted any calculations yet)?

Thanks,

bw